LONDON (Alliance News) - FTSE 100 pharma company GlaxoSmithKline PLC said Friday a European Medicines Agency committee has recommended its asthma drug Nucala for patients between six and 17 years of age.
The Committee for Medicinal Products for Human Use recommended Nucala as a treatment for asthma patients suffering with eosinophilic inflammation, which causes inflammation in the lungs and increases asthma attacks.
Glaxo said that asthma is the most common chronic childhood disease in childhood. The company noted that severe asthma that unresponsive to current treatments has been reported in approximately 4.5% of children with asthma.
Nucala has already been approved in, among other markets, the US and Europe as an add-on treatment for asthma patients with eosinophilic inflammation.
Shares in Glaxo were up 1.1% at 1,552.80 pence on Friday.
Glaxosmithkline (GSK)